-
Je něco špatně v tomto záznamu ?
Lipopolysaccharide-induced necroptosis of brain microvascular endothelial cells can be prevented by inhibition of endothelin receptors
Y. Abdul, R. Ward, G. Dong, A. Ergul
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- antagonisté endotelinového receptoru farmakologie MeSH
- apoptóza účinky léků fyziologie MeSH
- endoteliální buňky účinky léků metabolismus MeSH
- lidé MeSH
- lipopolysacharidy toxicita MeSH
- mikrocévy účinky léků metabolismus MeSH
- mozek účinky léků metabolismus MeSH
- nekróza chemicky indukované metabolismus MeSH
- receptory endotelinů metabolismus MeSH
- transformované buněčné linie MeSH
- viabilita buněk účinky léků fyziologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Over activation of the endothelin-1 (ET-1) system in disease states contributes to endothelial dysfunction. On the other hand, ET-1 promotes proliferation and survival of endothelial cells. Regulation of programmed cell death (PCD) pathways is critical for cell survival. Recently discovered necroptosis (regulated necrosis) is a pathological PCD mechanism mediated by the activation of toll like receptor 4 (TLR4), which also happens to stimulate ET-1 production in dendritic cells. To establish the effect of ET-1 on PCD and survival of human brain microvascular endothelial cells (BMVECs) under control and inflammatory conditions, BMVECs were treated with ET-1 (10 nM, 100 nM and 1 microM) or lipopolysaccharide (LPS, 100 ng/ml). ET receptors were blocked with bosentan (10 microM). Under normal growth conditions, exogenous ET-1 reduced BMVEC viability and migration at a relatively high concentration (1 microM). This was accompanied with activation of necroptosis and apoptosis marker genes. LPS decreased endogenous ET-1 secretion, increased ET(B) receptor expression and activated necroptosis. Even though ET-1 levels were low (less than 10 nM levels used under normal growth conditions), blocking of ET receptors with bosentan inhibited the necroptosis pathway and improved the cell migration ability of BMVECs, suggesting that under inflammatory conditions, ET-1 activates PCD pathways in BMVECs even at physiological levels.
Charlie Norwood Veterans Affairs Medical Center Augusta GA USA
Department of Neuroscience and Regenerative Medicine Augusta University Augusta GA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19005324
- 003
- CZ-PrNML
- 005
- 20210531151456.0
- 007
- ta
- 008
- 190204s2018 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.933842 $2 doi
- 035 __
- $a (PubMed)29947542
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Abdul, Y. $u Department of Physiology, Augusta University, Augusta, GA, USA
- 245 10
- $a Lipopolysaccharide-induced necroptosis of brain microvascular endothelial cells can be prevented by inhibition of endothelin receptors / $c Y. Abdul, R. Ward, G. Dong, A. Ergul
- 520 9_
- $a Over activation of the endothelin-1 (ET-1) system in disease states contributes to endothelial dysfunction. On the other hand, ET-1 promotes proliferation and survival of endothelial cells. Regulation of programmed cell death (PCD) pathways is critical for cell survival. Recently discovered necroptosis (regulated necrosis) is a pathological PCD mechanism mediated by the activation of toll like receptor 4 (TLR4), which also happens to stimulate ET-1 production in dendritic cells. To establish the effect of ET-1 on PCD and survival of human brain microvascular endothelial cells (BMVECs) under control and inflammatory conditions, BMVECs were treated with ET-1 (10 nM, 100 nM and 1 microM) or lipopolysaccharide (LPS, 100 ng/ml). ET receptors were blocked with bosentan (10 microM). Under normal growth conditions, exogenous ET-1 reduced BMVEC viability and migration at a relatively high concentration (1 microM). This was accompanied with activation of necroptosis and apoptosis marker genes. LPS decreased endogenous ET-1 secretion, increased ET(B) receptor expression and activated necroptosis. Even though ET-1 levels were low (less than 10 nM levels used under normal growth conditions), blocking of ET receptors with bosentan inhibited the necroptosis pathway and improved the cell migration ability of BMVECs, suggesting that under inflammatory conditions, ET-1 activates PCD pathways in BMVECs even at physiological levels.
- 650 _2
- $a apoptóza $x účinky léků $x fyziologie $7 D017209
- 650 _2
- $a mozek $x účinky léků $x metabolismus $7 D001921
- 650 _2
- $a transformované buněčné linie $7 D002461
- 650 _2
- $a viabilita buněk $x účinky léků $x fyziologie $7 D002470
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a endoteliální buňky $x účinky léků $x metabolismus $7 D042783
- 650 _2
- $a antagonisté endotelinového receptoru $x farmakologie $7 D065128
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lipopolysacharidy $x toxicita $7 D008070
- 650 _2
- $a mikrocévy $x účinky léků $x metabolismus $7 D055806
- 650 _2
- $a nekróza $x chemicky indukované $x metabolismus $7 D009336
- 650 _2
- $a receptory endotelinů $x metabolismus $7 D017466
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ward, R. $u Department of Neuroscience and Regenerative Medicine, Augusta University, Augusta, GA, USA
- 700 1_
- $a Dong, G. $u Department of Physiology, Augusta University, Augusta, GA, USA
- 700 1_
- $a Ergul, A. $u Department of Physiology, Augusta University, Augusta, GA, USA; Charlie Norwood Veterans Affairs Medical Center, Augusta, GA, USA
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 67, Suppl. 1 (2018), s. S227-S236
- 773 0_
- $t ET-15 $g (2018), s. S227-S236 $w MED00206979
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29947542 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20190204 $b ABA008
- 991 __
- $a 20210531151455 $b ABA008
- 999 __
- $a ok $b bmc $g 1376287 $s 1043529
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 67 $c Suppl. 1 $d S227-S236 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- BMC __
- $a 2018 $d S227-S236 $m ET-15 $x MED00206979
- LZP __
- $b NLK118 $a Pubmed-20190204